Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyMolina Crinecerfont Coverage Policy Update | OpenP…
    Ask Trek AI about this page
    ModifiedMolina HealthcarePolicy C29356-A

    Classic Congenital Adrenal Hyperplasia (CAH): Crinecerfont Coverage

    Customize your policy alerts

    Sign up for Molina Healthcare Policy C29356-A alerts

    Get alerted when Policy C29356-A changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and coverage of oral crinecerfont (Crenessity) for adults and pediatric patients at least 4 years old with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Coverage requires documented adjunctive glucocorticoid use, stable supraphysiologic glucocorticoid dosing, applicable formulation criteria, and involvement by a board-certified endocrinologist.

    Policy Summary
    PayerMolina Healthcare
    PolicyClassic Congenital Adrenal Hyperplasia (CAH): Crinecerfont Coverage
    Policy CodePolicy C29356-A
    Change TypeModified
    Effective DateSeptember 24, 2026
    Next Review DateJuly 1, 2027
    Key ActionSubmit prior authorization documentation confirming classic CAH due to 21-hydroxylase deficiency, adjunctive glucocorticoid use, stable supraphysiologic dosing, and any oral-solution qualification.
    SourceLink
    POLICY UPDATE CHANGES

    New coverage criteria were created in Q2 2025.

    An Appendix revision was identified in Q3 2026.

    The available dosage forms section was revised in Q3 2025.

    Age 4+FDA-approved age range
    >12 mg/m²/dayPediatric glucocorticoid threshold
    >13 mg/m²/dayAdult glucocorticoid threshold

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    6 months
    Initial authorization
    12 monthsContinuation authorization
    200 mg twice dailyMaximum dose with CYP3A4 inducer

    Coverage Criteria

    Initial Therapy Criteria

    Covered when all initial therapy requirements are met.

    Initial therapy

    • Diagnosis and adjunctive treatment: Member has a confirmed diagnosis of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and crinecerfont will be used adjunctively with glucocorticoid replacement; the member currently requires stable supraphysiologic glucocorticoid dosing

      Documentation required

    • Stable glucocorticoid dose threshold

      • Pediatric threshold: Pediatric member's glucocorticoid dose exceeds 12 mg/m²/day in hydrocortisone dose equivalents>12 mg/m²/day
      • Adult threshold: Adult member's glucocorticoid dose exceeds 13 mg/m²/day in hydrocortisone dose equivalents>13 mg/m²/day
    • Oral solution qualification

      • Pediatric weight criterion: Member is a pediatric patient weighing less than 55 kg<55 kg
      • Swallowing limitation criterion: Documentation supports that the member is unable to swallow tablets

    Continuation Therapy Criteria

    Covered when all continuation therapy requirements are met.

    Continuation therapy

    • Adherence is at least 85% as verified by the prescriber or member medication fill history, or adherence is less than 85% because surgery or treatment of an infection caused temporary discontinuation≥85% unless qualifying temporary interruption
    • Safety: The prescriber attests to, or the clinical reviewer finds, no evidence of intolerable adverse effects or drug toxicity
    • Clinical response: Positive clinical response is demonstrated by a reduction in daily glucocorticoid doseReduction in daily glucocorticoid dose

      Documentation required

    Use of Crenessity (crinecerfont) for indications other than the policy-supported treatment of classic congenital adrenal hyperplasia is considered experimental or investigational and follows Molina’s Off-Label policy.

    Crenessity (crinecerfont) is contraindicated in patients with hypersensitivity to crinecerfont or any excipient of Crenessity.

    Coding and Clinical Thresholds

    HCPCS CodeHCPCS
    NANo HCPCS code provided in the policy's coding/billing section.
    Pediatric stable glucocorticoid dose
    Pediatric threshold>12 mg/m²/day in hydrocortisone dose equivalents
    Dose requirementThe glucocorticoid dose must be stable and exceed the applicable threshold.
    Applies toPediatric patients receiving glucocorticoid treatment for classic congenital adrenal hyperplasia.
    Adult stable glucocorticoid dose
    Adult threshold>13 mg/m²/day in hydrocortisone dose equivalents
    Dose requirementThe glucocorticoid dose must be stable and exceed the applicable threshold.

    Provider Documentation and Authorization Actions

    Prior Authorization

    Initial Authorization Documentation Required

    Submit an initial authorization request with complete clinical documentation showing the member meets Molina’s coverage criteria for Crenessity (crinecerfont). Include the diagnosis, adjunctive glucocorticoid use, stable supraphysiologic dosing, applicable formulation criteria, and required prescriber documentation.

    • Initial authorization approval duration: 6 months.
    • Include medical records and other supporting evidence required for Molina’s coverage determination.
    Prior Authorization

    Continuation Authorization Requirements

    For reauthorization, document continued treatment eligibility, adherence, clinical response, safety, and ongoing adjunctive use with glucocorticoids.

    • Continuation authorization approval duration: 12 months.
    • Document adherence, response shown by reduced daily glucocorticoid dose, absence of intolerable adverse effects or toxicity, and continued crinecerfont use.

    Clinical Background

    Classic congenital adrenal hyperplasia (CAH) is an autosomal recessive disorder of impaired cortisol synthesis, most commonly caused by 21-hydroxylase deficiency. Reduced cortisol and aldosterone production increases adrenocorticotropic hormone stimulation and adrenal androgen production. Classic CAH is the more severe form and may result in adrenal crisis, early puberty, virilization, growth acceleration, and reproductive complications.

    Glucocorticoids are standard treatment for classic CAH but are often required at supraphysiologic doses, which may contribute to obesity, hypertension, insulin resistance, diabetes, reduced bone density, and fracture risk. Crinecerfont, a corticotropin-releasing factor type 1 receptor antagonist, is used adjunctively to reduce adrenocorticotropic hormone and adrenal androgen production and support reduction of glucocorticoid dosing.

    Policy Definitions

    Classic CAH due to 21-hydroxylase deficiency
    ConditionClassic congenital adrenal hyperplasia is caused by deficiency of the 21-hydroxylase enzyme.
    Cortisol synthesisThe enzyme deficiency results in impaired cortisol synthesis.
    Androgen productionImpaired cortisol synthesis is associated with increased adrenal androgen production.
    Crinecerfont
    MedicationCrinecerfont is a corticotropin-releasing factor type 1 (CRF1) receptor antagonist.
    Treatment roleIt is used as adjunctive treatment with glucocorticoid replacement.
    Therapeutic purpose

    Initial Therapy Requirements

    Initial Therapy Criteria

    Initial therapy is covered when all of the following requirements are met.

    Initial therapy

    • Diagnosis: Member has a confirmed diagnosis of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency

      Documentation required

    • Adjunctive glucocorticoid treatment: Crinecerfont will be used as adjunctive treatment with glucocorticoid replacement

      Documentation required

    • Stable supraphysiologic glucocorticoid dosing: Member currently requires supraphysiologic glucocorticoid dosing to control the condition and the dose is currently stable

      Documentation required

    Continuation Therapy Requirements

    Continuation Therapy Criteria

    Continuation therapy is covered when all of the following reauthorization requirements are met.

    Continuation therapy

    • Adherence to therapy is at least 85% as verified by the prescriber or member medication fill history, or adherence is less than 85% because surgery or treatment of an infection caused temporary discontinuation≥85% unless qualifying temporary interruption
    • Safety: The prescriber attests to, or the clinical reviewer finds, no evidence of intolerable adverse effects or drug toxicity
    • Positive clinical response is demonstrated by a reduction in daily glucocorticoid doseReduction in daily glucocorticoid dose

      Documentation required

    Quantity and Dose Limits

    Crinecerfont quantity limits and dosing
    10 kg to less than 20 kg25 mg orally twice daily
    20 kg to less than 55 kg50 mg orally twice daily
    55 kg or more100 mg orally twice daily
    Crinecerfont dosing with a strong or moderate CYP3A4 inducer
    10 kg to less than 20 kg50 mg orally twice daily with a meal
    20 kg to less than 55 kg100 mg orally twice daily with a meal
    55 kg or more200 mg orally twice daily with a meal; maximum quantity limit is 200 mg twice daily

    Site of Care and Administration

    Billing Rule

    Use the pharmacy benefit for self-administered oral therapy

    Oral medication is recommended for pharmacy benefit coverage and patient self-administration.

    Policy Summary
    PayerMolina Healthcare
    PolicyClassic Congenital Adrenal Hyperplasia (CAH): Crinecerfont Coverage
    Policy CodePolicy C29356-A
    Change TypeModified
    Effective DateSeptember 24, 2026
    Next Review DateJuly 1, 2027
    Key ActionSubmit prior authorization documentation confirming classic CAH due to 21-hydroxylase deficiency, adjunctive glucocorticoid use, stable supraphysiologic dosing, and any oral-solution qualification.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Clinical ThresholdsProvider Documentation and Authorization ActionsClinical BackgroundPolicy DefinitionsInitial Therapy RequirementsContinuation Therapy RequirementsQuantity and Dose LimitsSite of Care and Administration
    Ongoing adjunctive treatment: Member continues to use crinecerfont adjunctively with glucocorticoids
  1. Oral solution qualification

    • Pediatric weight criterion: Member is a pediatric patient weighing less than 55 kg<55 kg
    • Swallowing limitation criterion: Documentation supports that the member is unable to swallow tablets
  2. Applies to
    Adults receiving glucocorticoid treatment for classic congenital adrenal hyperplasia.
    Minimum age
    Minimum age4 years of age and older
    PopulationAdults and pediatric patients are eligible when the applicable coverage criteria are met.
    IndicationClassic congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
    Documentation Required

    General Supporting Documentation

    Provide complete medical rationale and supporting records with the request. Molina may request additional documentation, including patient records, test results, and credentials of the ordering or performing provider.

    • Documentation must support medical necessity, a non-investigational use, and coverage within the member’s benefit.
    Documentation Required

    Confirmed Classic CAH Diagnosis Required

    Document a confirmed diagnosis of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency (21-OHD).

    • Diagnosis documentation is required for coverage.
    Documentation Required

    Glucocorticoid Treatment and Dose

    Document that crinecerfont will be used adjunctively with glucocorticoid replacement and that the member requires a stable supraphysiologic glucocorticoid dose to control the condition.

    • Pediatric patients: hydrocortisone-equivalent glucocorticoid dose must be >12 mg/m²/day.
    • Adult patients: hydrocortisone-equivalent glucocorticoid dose must be >13 mg/m²/day.
    • Document that the qualifying dose is currently stable.
    Documentation Required

    Continuation Documentation

    For continuation requests, document adherence and ongoing benefit and confirm that treatment remains safe and clinically appropriate.

    • Adherence must be at least 85% based on prescriber verification or medication fill history, unless lower adherence resulted from temporary discontinuation for surgery or infection treatment.
    • Document positive clinical response through reduction in daily glucocorticoid dose.
    • Document no intolerable adverse effects or drug toxicity.
    • Confirm continued adjunctive use of crinecerfont with glucocorticoids.

    Unsupported block type: documentation

    Unsupported block type: documentation

    Denial Risk

    Insufficient Support Risks Denial

    Incomplete or unsupported documentation may prevent Molina from confirming medical necessity and may result in denial or other appropriate action.

    • Provide complete patient records, test results, medical rationale, and provider credentials when applicable.
    • Documentation must support that the requested drug is medically necessary, not investigational or experimental, and within the member’s benefits.
    Denial Risk

    Unmet Clinical Criteria

    Coverage is at risk when required clinical criteria are not met or cannot be verified in the submitted records.

    • No confirmed classic CAH due to 21-OHD diagnosis documentation.
    • No documentation of adjunctive glucocorticoid treatment.
    • No stable qualifying supraphysiologic glucocorticoid dose.
    • Oral solution request does not meet the pediatric weight or tablet-swallowing criterion.
    • Continuation request lacks required adherence, response, safety, or ongoing adjunctive-use documentation.
    Denial Risk

    Prescriber Requirement

    The prescription must be issued by a board-certified endocrinologist or supported by consultation with one.

    • For consultation-based prescribing, include consultation notes with the initial authorization and each reauthorization request.
    Denial Risk

    Non-Covered or Investigational Use

    Uses of Crenessity (crinecerfont) outside the covered classic CAH indication are considered experimental or investigational and are handled under Molina’s Off-Label policy.

    • Do not submit unsupported indications as covered uses under this guideline.
    Denial Risk

    Hypersensitivity Contraindication

    Crenessity (crinecerfont) is contraindicated for members with hypersensitivity to crinecerfont or any Crenessity excipients.

    • Document that no contraindicating hypersensitivity is present before requesting or continuing therapy.
    It is indicated to control androgens in adults and pediatric patients 4 years of age and older with classic congenital adrenal hyperplasia.
    Crinecerfont mechanism and effects
    MechanismCrinecerfont blocks corticotropin-releasing factor from binding to the CRF1 receptor.
    ACTH effectBlocking CRF1 signaling reduces adrenocorticotropic hormone (ACTH).
    Androgen effectReduced ACTH lowers adrenal androgen production and helps control adrenal androgen levels.
    TARTs
    Full termTARTs are testicular adrenal rest tumors.
    Associated conditionThey may occur in males with classic congenital adrenal hyperplasia.
    Clinical contextTARTs are associated with classic CAH-related adrenal androgen excess.
  3. Applicable dose threshold

    • Pediatric dose: Pediatric member's glucocorticoid dose exceeds 12 mg/m²/day>12 mg/m²/day

      In hydrocortisone dose equivalents

    • Adult dose: Adult member's glucocorticoid dose exceeds 13 mg/m²/day>13 mg/m²/day

      In hydrocortisone dose equivalents

  4. Oral solution qualification

    • Pediatric weight criterion: Member is a pediatric patient weighing less than 55 kg<55 kg
    • Swallowing limitation criterion: Documentation supports that the member is unable to swallow tablets
  5. Prescriber requirement: Crinecerfont is prescribed by or in consultation with a board-certified endocrinologist

    If prescribed in consultation, submit consultation notes with the initial request and reauthorization requests

  6. Age requirement: Member is 4 years of age or older≥4 years
  7. Continued adjunctive treatment: Member continues to use crinecerfont adjunctively with glucocorticoids

    Documentation required

  8. Oral solution qualification

    • Pediatric weight criterion: Member is a pediatric patient weighing less than 55 kg<55 kg
    • Swallowing limitation criterion: Documentation supports that the member is unable to swallow tablets
  9. Prescriber requirement: Crinecerfont is prescribed by or in consultation with a board-certified endocrinologist

    If prescribed in consultation, submit consultation notes with the reauthorization request